Table 1.
Patient Demographics and Diagnostic Workup
| Age (yrs) |
Sex | Tumor Type |
Current Therapy |
Prior Therapies |
DIF | IIF | Salt Split Skin Analysis |
Time of Rash Onset (from start of Therapy) |
BP Elisa Titers (from time taken since start of therapy) |
|---|---|---|---|---|---|---|---|---|---|
| 80 | Male | Melanoma | Anti- PD-1 mAb |
Ipilimumab | + | + | + | 24 weeks |
At 33.9 weeks: BP180: 13.8* BP230: 10.0* At 47.0 weeks BP180: 25.6* BP230: 12.2* |
| 78 | Female | Melanoma | Anti- PD-1 mAb |
Ipilimumab | + | + | + | 17.9 weeks |
At 44.1 weeks: BP180: 72* BP230: 21.7* |
| 85 | Male | NSCLC | Anti- PD-L1 mAb |
Carboplatin + Gemcitabine |
+ | NA | NA | 6.1 weeks |
At 55.1 weeks: BP180: 1.1* BP230: 0.9* |
NSCLC= Non-small cell lung cancer, mAb= monoclonal antibody, NA= not applicable (not completed), DIF= direct immunofluroescence, IIF= immunofixation, BP ELISA= bullous pemphigoid enzyme-linked immunosorbent assay,
*
BP ELISA taken during steroid therapy.